Literature DB >> 21287560

Treatment of postinfectious olfactory disorders with minocycline: a double-blind, placebo-controlled study.

Jens Reden1, Birgit Herting, Katja Lill, Robert Kern, Thomas Hummel.   

Abstract

OBJECTIVES/HYPOTHESIS: Infection of the upper respiratory tract is one of the most common causes of olfactory loss. One of the possible underlying pathologic pathways is an increase of apoptosis of olfactory receptor neurons. Therefore, treatment with the antibiotic minocycline, which has been shown to act as an antiapoptotic agent, is thought to accelerate improvement of olfactory function. To investigate this idea, 55 patients with postinfectious olfactory dysfunction were tested for their olfactory ability. STUDY
DESIGN: Randomized, prospective, double-blind, placebo-controlled.
METHODS: Olfactory function was examined by means of a standardized psychophysical method (Sniffin' Sticks) before and 7 months after a 3-week treatment with either minocycline (2 × 50 mg/d) or a placebo.
RESULTS: Statistical analyses did not reveal any influence of the treatment on the progress of olfactory function, possibly indicating that pathologic changes other than apoptosis contribute to postinfectious olfactory loss, either on a peripheral level (e.g., scarring/reorganization of the olfactory epithelium) or on a central nervous level.
CONCLUSIONS: In conclusion, the present results indicate that minocycline in the given dosage has little or no effect on the recovery of human olfactory function following postinfectious olfactory loss. However, spontaneous recovery is found in approximately 20% of the patients over an observation period of 7 months.
Copyright © 2011 The American Laryngological, Rhinological, and Otological Society, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21287560     DOI: 10.1002/lary.21401

Source DB:  PubMed          Journal:  Laryngoscope        ISSN: 0023-852X            Impact factor:   3.325


  20 in total

1.  [Olfactory disorders and their therapy].

Authors:  A Hähner; T Hummel; B A Stuck
Journal:  HNO       Date:  2014-12       Impact factor: 1.284

2.  Management of Smell Dysfunction.

Authors:  Livije Kalogjera; Davor Dzepina
Journal:  Curr Allergy Asthma Rep       Date:  2012-02-02       Impact factor: 4.806

3.  Treatment strategies for postviral olfactory dysfunction: A systematic review.

Authors:  Samuel N Helman; Jonah Adler; Aria Jafari; Sasha Bennett; Jackson R Vuncannon; Ashley C Cozart; Sarah K Wise; Merin E Kuruvilla; Joshua M Levy
Journal:  Allergy Asthma Proc       Date:  2022-03-01       Impact factor: 2.587

4.  Olfactory training for patients with olfactory loss after upper respiratory tract infections.

Authors:  K Geißler; H Reimann; H Gudziol; T Bitter; O Guntinas-Lichius
Journal:  Eur Arch Otorhinolaryngol       Date:  2013-10-06       Impact factor: 2.503

5.  Pathophysiology of Olfactory Disorders and Potential Treatment Strategies.

Authors:  Stefania Goncalves; Bradley J Goldstein
Journal:  Curr Otorhinolaryngol Rep       Date:  2016-06

6.  Short-term effect of caffeine on olfactory function in hyposmic patients.

Authors:  Thomas Meusel; Janine Albinus; Antje Welge-Luessen; Antje Hähner; Thomas Hummel
Journal:  Eur Arch Otorhinolaryngol       Date:  2016-01-07       Impact factor: 2.503

7.  Smell and taste disorders.

Authors:  Thomas Hummel; Basile N Landis; Karl-Bernd Hüttenbrink
Journal:  GMS Curr Top Otorhinolaryngol Head Neck Surg       Date:  2012-04-26

8.  Hidden consequences of olfactory dysfunction: a patient report series.

Authors:  Andreas Keller; Dolores Malaspina
Journal:  BMC Ear Nose Throat Disord       Date:  2013-07-23

9.  Interventions for the prevention of persistent post-COVID-19 olfactory dysfunction.

Authors:  Katie E Webster; Lisa O'Byrne; Samuel MacKeith; Carl Philpott; Claire Hopkins; Martin J Burton
Journal:  Cochrane Database Syst Rev       Date:  2021-07-22

10.  Interventions for the treatment of persistent post-COVID-19 olfactory dysfunction.

Authors:  Lisa O'Byrne; Katie E Webster; Samuel MacKeith; Carl Philpott; Claire Hopkins; Martin J Burton
Journal:  Cochrane Database Syst Rev       Date:  2021-07-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.